ERBB2 and breast carcinoma: Preoperative biopsy and postoperative pathology showed that 79 patients (72.5%) had hormone receptor (HR) positive breast cancer, 71 patients (65.2%) had human epidermal growth factor receptor 2 (HER2) positive breast cancer, and 8 patients (7.3%) had triple-negative breast cancer (TNBC).